Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

摘要: Monoclonal antibodies bevacizumab and cetuximab both improve overall survival (OS), progression free (PFS) response rate (ORR) when combined with irinotecan-containing regimens. The optimal sequence of these monoclonal in combination chemotherapy is controversial. This study analysed the efficacy plus Folfiri after same regimen patients metastatic colorectal cancer (mCRC). Patients are eligible if progressive disease (PD) Folfiri-bevacizumab; ECOG PS 0–1. Primary endpoint control (DCR:ORR stable > 6 months); secondary endpoints: ORR, PFS, duration response, OS toxicity. ORR DCR were reported their confidence interval at 95%. Kaplan-Meier method was used for PFS evaluation. Results: 54 enrolled to receive Folfiri-cetuximab PD Folfiri-bevacizumab treatment. Median age 65 (43–80), M/F 31/23, 0/1 36/ 18, WT Kras 33(61%). 64.8% (CI 95% 52.1-77.5). Among group or first line treatment, 13.3% them obtained a second line. For treatment median months clinical benefit 7 months. 22.2% 11.1-33.3). progression-free 6–8). 14 11–17). No grade 4 toxicity observed. Data suggest that this sequential therapy active well tolerated. At maintenance change antibody showed mCRC.